Skip to main content
CanSino Biologics Inc. (HKG:6185)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
29.84
-2.20 (-6.87%)
Apr 29, 2026, 4:08 PM HKT

CanSino Biologics Revenue

In the year 2025, CanSino Biologics had annual revenue of 1.07B CNY with 26.18% growth. CanSino Biologics had revenue of 375.34M in the quarter ending December 31, 2025, with 34.40% growth.

Revenue
1.07B CNY
Revenue Growth
+26.18%
P/S Ratio
10.86
Revenue / Employee
957.76K CNY
Employees
1,115
Market Cap
12.90B HKD

Revenue Chart

* This company reports financials in CNY.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20251.07B221.57M26.18%
Dec 31, 2024846.34M489.25M137.01%
Dec 31, 2023357.08M-677.51M-65.49%
Dec 31, 20221.03B-3.27B-75.94%
Dec 31, 20214.30B4.27B17,174.82%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Consun Pharmaceutical Group 3.80B
Xuanzhu Biopharmaceutical 57.61M
Sihuan Pharmaceutical Holdings Group 2.91B
Ab&B Bio-Tech CO., LTD. JS 354.77M
Luye Pharma Group 7.02B
Shandong Xinhua Pharmaceutical Company 9.74B
The United Laboratories International Holdings 14.70B
China Traditional Chinese Medicine Holdings Co. 16.41B
Revenue Rankings

CanSino Biologics News

More News